RxSight, Inc.
NASDAQ•RXST
執行長: Dr. Ronald M. Kurtz M.D.
板塊: Healthcare
行業: Medical - Devices
上市日期: 2021-07-30
RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
聯絡資訊
市值
$302.48M
本益比 (TTM)
-7.8
26.6
股息率
--
52周最高
$27.13
52周最低
$6.32
52周範圍
排名59Top 87.6%
2.2
F-Score
改良版 Piotroski 分析
基於 6 年期基本面
疲弱 • 2.2 / 9 分
評分區間 (0-9)
8-9: 價值優異
6-7: 基本面強勁
4-5: 整體穩健
0-3: 表現疲弱
資料區間: 2020-2025
財務儀表板
Q4 2025 數據
營業收入
$32.61M+0.00%
近4季度走勢
每股收益
-$0.22+0.00%
近4季度走勢
自由現金流
$17.09M+0.00%
近4季度走勢
2025 Annual 財報亮點
核心亮點
Gross Margin Improvement Gross Profit reached $103.0M, up 4.1%; favorable LAL sales mix improved gross margin to 76.6%.
LAL Utilization Growth LAL sales increased 11,560 units year-over-year, driven by expanding installed base of 1,134 LDD units.
Strong Cash Position Total cash and short-term investments stand at $228.1M as of December 31, 2025, ensuring liquidity.
Adoption Milestones Reached Nearly 300,000 LALs implanted since inception through year-end 2025, validating commercial traction and adoption efforts.
關注風險
Sales Volume Decline Total Sales decreased 3.9% to $134.5M, primarily due to 47% drop in LDD unit sales for the year.
Widening Operating Loss Operating Loss widened 30.7% to $(48.2M) as SG&A expenses increased 11.1% to $112.7M.
Pending Litigation Exposure Facing securities class action and shareholder derivative lawsuits; adverse resolution could materially impact business.
Intense Market Competition Primary competitors (Alcon, J&J) control 75% of U.S. premium IOL market, posing intense competition risk.
未來展望
Focus on Revenue Growth Commercial realignment initiatives focus on renewed revenue growth via increased LAL utilization at existing practices.
Increased R&D Investment R&D spending increased 12.2% to $38.5M, targeting clinical outcomes, customer experience, and cost reduction.
Selective International Expansion Planning selective international expansion, holding regulatory approvals in Europe, Canada, Mexico, and Asia markets.
Capital Sufficiency Confirmed Expect current cash reserves of $228.1M to fund operations for at least the next 12 months.
同行對比
營業收入 (TTM)
$329.52M
$236.35M
$212.69M
毛利率 (最新季度)
91.5%
85.5%
80.6%
關鍵指標
股票代碼 | 市值 | 本益比 (TTM) | 股東權益報酬率 (TTM) | 負債率 |
|---|---|---|---|---|
| BFLY | $967.60M | -12.5 | -35.3% | 6.9% |
| SRDX | $614.51M | -34.8 | -15.6% | 19.2% |
| TCMD | $604.28M | 31.6 | 9.3% | 5.8% |
長期趨勢
近4季度
營業收入
淨利
營運現金流
4季度營業收入複合增長率
-4.9%
基本持平
4季度淨利複合增長率
N/M
盈利狀態轉變
現金流穩定性
25%
現金流需要關注
深度研究
下次財報:2026年5月12日
每股收益:-$0.31
|營業收入:$29.97M
財務數據
電話會議
財務報告
新聞
損益表
資產負債表
現金流量表
財務比率
變化率
損益表 | 過去12個月 |
|---|
無資料